Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?
Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?
Created by
Presenter
Professor of Endocrinology and Metabolism School of Medicine, University of Pisa Chief of the Section of Diabetes University of Pisa, Italy Clinical Associate Professor of Medicine University of Texas, San Antonio Health Science Center San Antonio, Texas